1 min read
Baird Downgrades Insulet to Neutral and Cuts Price Target to $158
The firm lowered its target from $200 after a survey found weaker brand loyalty to automated insulin delivery systems than in the past.

Baird downgraded Insulet to Neutral from Overweight and cut its price target to $158 from $200 after a survey found weaker brand loyalty to automated insulin delivery systems than in the past.
The revised target represented about 19% upside from Friday’s close.